Clinical Care Options Breast Cancer This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Combination Approaches and Extending the Use of CDK4/6 Inhibitors Beyond ER-Positive Breast Cancer
Slideset - The third of 3 downloadable slidesets from a satellite symposium at the 2017 annual meeting in Chicago: Richard Finn, MD; Gary K. Schwartz, MD; and Geoffrey Shapiro, MD, PhD, review key data on combining CDK4/6 inhibitors with hormone therapy, PI3K inhibitors, and others in multiple cancers. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - June 8, 2017 Category: Cancer & Oncology Source Type: research

MONARCH 2: Phase III Study of Abemaciclib + Fulvestrant in HR+/HER2- Advanced Breast Cancer After Progression on Endocrine Therapy
Slideset - Addition of the CDK4/6 inhibitor abemaciclib to fulvestrant reduced the risk of disease progression by 45%, with an acceptable tolerability profile. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - June 7, 2017 Category: Cancer & Oncology Source Type: research

Phase III Investigation of Neoadjuvant Carboplatin ± Veliparib in Combination With Chemotherapy in Early-Stage TNBC
Slideset - Addition of veliparib and carboplatin to neoadjuvant T→ AC did not increase pCR rate over carboplatin plus T→ AC alone. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - June 7, 2017 Category: Cancer & Oncology Source Type: research

MONARCH 2: Phase III Study of Abemaciclib + Fulvestrant in HR+/HER2- Advanced Breast Cancer After Progression on Endocrine Therapy
Slideset - Addition of the CDK4/6 inhibitor abemaciclib to fulvestrant reduced the risk of disease progression by 45%, with an acceptable tolerability profile. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - June 7, 2017 Category: Cancer & Oncology Source Type: research

ALTERNATIVE: Dual HER2 Blockade + Aromatase Inhibitor in Postmenopausal Women With HER2+, HR+ MBC
Slideset - Significantly improved PFS and ORR observed with addition of lapatinib to trastuzumab plus investigator-selected aromatase inhibitor. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - June 6, 2017 Category: Cancer & Oncology Source Type: research

Phase I/II ECHO-202/KEYNOTE-037: Safety of Epacadostat + Pembrolizumab in Solid Tumors
Slideset - In a phase II expansion study, the combination had a low incidence of grade 3/4 adverse events across all tumor types evaluated. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - June 5, 2017 Category: Cancer & Oncology Source Type: research

APHINITY: Adjuvant Pertuzumab + Trastuzumab and Chemotherapy in HER2+ EBC
Slideset - Pertuzumab addition significantly reduced risk of invasive DFS at 3 years. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - June 5, 2017 Category: Cancer & Oncology Source Type: research

LOTUS: Investigation of Ipatasertib, a Novel Akt Inhibitor, in Combination With Paclitaxel as Frontline Therapy for Metastatic TNBC
Slideset - The addition of ipatasertib to paclitaxel improved PFS for patients with metastatic TNBC, with the greatest benefit observed in a prespecified subgroup analysis of patients withPIK3CA/AKT1/PTEN-altered tumors. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - June 4, 2017 Category: Cancer & Oncology Source Type: research

KEYNOTE-086 (Cohort A): Phase II Evaluation of Pembrolizumab Monotherapy in Heavily Pretreated Metastatic TNBC
Slideset - Pembrolizumab monotherapy was well tolerated and active in a subset of pretreated metastatic TNBC patients, with promising preliminary survival results observed in patients with CR, PR, or SD. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - June 4, 2017 Category: Cancer & Oncology Source Type: research

Selective CDK4/6 Inhibitors in Cancer: Moving Beyond Breast Cancer
Learning Module - Richard Finn, MD; Gary K. Schwartz, MD; and Geoffrey Shapiro, MD, PhD, discuss the supporting rationale and emerging role of selective CDK4/6 inhibitors in multiple types of cancer. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - April 14, 2017 Category: Cancer & Oncology Source Type: research

Selective CDK4/6 Inhibitors in Cancer: Moving Beyond Breast Cancer
Slideset - In this downloadable slideset, Richard Finn, MD, Gary K. Schwartz, MD, and Geoffrey Shapiro, MD, PhD provide insight on the rationale for targeting cyclin dependent kinases 4 and 6 in cancer and highlight emerging clinical data with selective CDK4/6 inhibitors in multiple cancers. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - April 14, 2017 Category: Cancer & Oncology Source Type: research

Building Bridges: Equipping Clinicians and Improving Clinician –Patient Partnerships in the Treatment of Metastatic Breast Cancer
Slideset - In this downloadable slideset, Kathy D. Miller, MD, reviews management strategies for patients with MBC based on the most recent evidence. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - February 16, 2017 Category: Cancer & Oncology Source Type: research

CCO Independent Conference Highlights of the 2016 European Society for Medical Oncology Annual Congress*
Learning Module - In this text module and accompanying downloadable slideset, experts review the most clinically relevant study results presented at the 2016 ESMO annual meeting across multiple different malignancies including advanced NSCLC, melanoma, breast cancer, ovarian cancer, and glioblastoma. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - January 4, 2017 Category: Cancer & Oncology Source Type: research

European Society of Medical Oncology 2016 Congress
Slideset - In this downloadable slideset, Margaret Callahan, MD, PhD, Shirish Gadgeel, MD, Ryan T. Merrell, MD, Bradley J. Monk, MD, FACS, FACOG, and Joyce O ’Shaughnessy, MD, review important clinical presentations across multiple cancers from the 2016 oncology meeting in Copenhagen. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - December 12, 2016 Category: Cancer & Oncology Source Type: research

Expert Guidance on Selecting Treatment for Metastatic Breast Cancer
Tool - Use this Interactive Decision Support Tool to enter your patient ’s specific presentation characteristics then compare your choice of therapy with expert recommendations from Kimberly L. Blackwell, MD; Sara Hurvitz, MD, FACP; Mohammad Jahanzeb, MD, FACP; Kathy D. Miller, MD; and Nicholas J. Robert, MD. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - December 9, 2016 Category: Cancer & Oncology Source Type: research